Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Spain / NCT05997615
Recruiting Phase 1

Safety, Pharmacokinetics, and Preliminary Efficacy of VIR-5500 (AMX-500) in Prostate Cancer

NCT05997615 · tracked via the Priya Life Science Spain tracker
Sponsor
Astellas Pharma Global Development, Inc
Phase
Phase 1
Started
2023-08-10
Last updated
2026-10-07

Condition(s) studied

Hormone-refractory Prostate Cancer

Investigational drug(s) / intervention(s)

VIR-5500Androgen receptor signaling inhibitor (ARSI)

VIR-5500: Pharmaceutical form: Solution for infusion Route of administration: Intravenous (IV) infusion

Androgen receptor signaling inhibitor (ARSI): Oral administration

Study summary

The study will be conducted in 4 parts and will commence with dose escalation of VIR-5500 as a monotherapy (Part 1), followed by combination escalation (Part 3a), monotherapy dose expansion (Part 2) and combination dose expansion (Part 4a).

* Part 1 (Monotherapy Dose Escalation): Single-agent VIR-5500 dose escalation
* Part 2 (Monotherapy Dose Expansion): Single-agent VIR-5500 dose expansion
* Part 3 (Combination Dose Escalation): VIR-5500 plus another therapeutic agent dose escalation Part 3a (Combination Dose Escalation): VIR-5500 in combination with an androgen receptor signaling inhibitor (ARSI)
* Part 4 (Combination Dose Expansion): VIR-5500 plus another therapeutic agent dose expansion Part 4a (Combination Dose Expansion): VIR-5500 in combination with an androgen receptor signaling inhibitor (ARSI)

Eligibility

Sex
MALE
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: Applicable to Parts 1 and 2 1. Have metastatic disease, defined by ≥ 1 metastatic lesion that is present on baseline computed tomography (CT), magnetic resonance imaging (MRI), or bone scan imaging 2. Have documented progressive mCRPC based on ≥ 1 of the criteria (per PCWG3) * PSA level ≥ 1 ng/mL that has increased on ≥ 2 successive occasions ≥ 1 week apart * Nodal or visceral progression as defined by RECIST v1.1 with PCWG3 modifications * Appearance of ≥ 2 new lesions in bone scan 3. Have been treated with ≥ 1 second-generation androgen-signaling inhibitor, including abiraterone, apalutamide, darolutamide, and/or enzalutamide 4. Have been treated with ≥ 1 prior taxane regimens (e.g., docetaxel, cabazitaxel) 5. Are deemed unsuitable for standard of care Applicable to Part 2, 3a and Part 4a, 1. Have metastatic CRPC, defined by ≥ 1 metastatic lesion that is present on baseline CT, MRI, or bone scan imaging that has documented progressive disease (PD) based on ≥ 1 of the following criteria (per PCWG3): * PSA level ≥ 1 ng/mL that has increased on ≥ 2 successive occasions ≥ 1 week apart * Nodal or visceral progression as defined by RECIST v1.1 with PCWG3 modifications * Appearance of ≥2 new lesions in bone scan 2. Participants with metastatic hormone sensitive prostate cancer (mHSPC) or with biochemical recurrent prostate cancer (BRPC) may also participate in select cohorts of this clinical trial. Exclusion Criteria: 1. Presence of dominant histopathological features representative of sarcomatoid, spindle cell, or neuroendocrine small cell components 2. Has acute or chronic infections 3. Has a concomitant medical or inflammatory condition that may increase the risk of toxicity to VIR-5500 (AMX-500), per the Investigator 4. Has lesions in proximity of vital organs 5. Has known active CNS metastases and/or carcinomatous meningitis The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Primary outcome measure(s)

  • All parts: Incidence of treatment emergent anti-drug antibodies (ADAs) to VIR-5500 — from the Cycle 1(each cycle is 21 or 28 days), Day 1 up to approximately 48 months
    Incidence and severity of AEs according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE)
  • Part 1 and 3a: Incidence of Dose Limiting Toxicities (DLTs) — from the Cycle 1(each cycle is 21 or 28 days), Day 1 up to Day 21 or Day 28
    Incidence and nature of DLTs according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE)
  • Part 2 and 4a: Prostate-Specific Antigen (PSA) response rate — from the Cycle 1(each cycle is 21 or 28 days), Day 1 up to approximately 48 months
  • Part 2 and 4a: Objective Response Rate (ORR) — from the Cycle 1(each cycle is 21 or 28 days), Day 1 up to approximately 48 months
  • Part 1 and 3a: Number of participants with treatment-emergent Adverse Events (AEs) — from the Cycle 1(each cycle is 21 or 28 days), Day 1 up to approximately 48 months
    Incidence and severity of AEs according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE)

Trial sites (22)

FacilityCityRegionStatus
Duarte Cancer Center Duarte California Recruiting
Lennar Foundation Cancer Center Irvine California Recruiting
UCI Health Chao Family Comprehensive Cancer Center Orange California Recruiting
Investigational Site Number: 403 Palo Alto California Recruiting
Chicago Cancer Center Zion Illinois Recruiting
Investigational Site Number: 401 Houston Texas Recruiting
Investigational Site number: 404 Fairfax Virginia Recruiting
Investigational Site Number: 400 Seattle Washington Recruiting
Investigational Site Number: 100 Melbourne Australia Recruiting
Investigational Site Number: 101 Sydney Australia Recruiting
Investigational Site Number: 251 Barcelona Spain Withdrawn
Investigational Site Number: 250 Barcelona Spain Recruiting
ES34007 Barcelona Spain Recruiting
ES34010 Logroño Spain Recruiting
Investigational Site Number: 254 Madrid Spain Recruiting
Investigational Site Number: 252 Madrid Spain Recruiting
ES34012 Madrid Spain Recruiting
ES34013 Málaga Spain Recruiting
Investigational Site Number: 253 Pamplona Spain Recruiting
ES34009 Valencia Spain Recruiting
GB44003 Leicester United Kingdom Recruiting
Investigational Site Number: 300 London United Kingdom Recruiting

More Astellas Pharma Global Development, Inc. trials in Spain

A Study of Zolbetuximab (IMAB362) Plus CAPOX Compared With Placebo Plus CAPOX as First-line Treatment of Subjects With Claudin (CLDN) 18.2-positive, HER2-negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (GLOW). Active, not recruiting
A Study to Confirm if Fezolinetant Helps Reduce Hot Flashes in Women With Breast Cancer Who Are Having Hormone Therapy Active, not recruiting
A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer Recruiting
Enfortumab Vedotin and Pembrolizumab vs. Chemotherapy Alone in Untreated Locally Advanced or Metastatic Urothelial Cancer Active, not recruiting
A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05997615 on ClinicalTrials.gov ↗ ← All trials in Spain